HIV Seropositivity

"HIV Seropositivity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).

Descriptor ID	D006679
MeSH Number(s)	C02.782.815.616.400.500 C02.800.801.400.500 C20.673.480.500
Concept/Terms	HIV Seropositivity HIV Seropositivity HIV Seropositivities Seropositivities, HIV Seropositivity, HIV AIDS Seropositivity AIDS Seropositivities Seropositivities, AIDS Seropositivity, AIDS Anti-HIV Positivity Anti HIV Positivity Anti-HIV Positivities Positivities, Anti-HIV Positivity, Anti-HIV HTLV-III Seropositivity HTLV III Seropositivity HTLV-III Seropositivities Seropositivities, HTLV-III Seropositivity, HTLV-III HIV Seroconversion HIV Seroconversions Seroconversion, HIV Seroconversions, HIV HTLV-III Seroconversion HTLV III Seroconversion HTLV-III Seroconversions Seroconversion, HTLV-III Seroconversions, HTLV-III AIDS Seroconversion AIDS Seroconversions Seroconversion, AIDS Seroconversions, AIDS HIV Antibody Positivity Antibody Positivities, HIV Antibody Positivity, HIV HIV Antibody Positivities Positivities, HIV Antibody Positivity, HIV Antibody

Below are MeSH descriptors whose meaning is more general than "HIV Seropositivity".

Diseases [C]
Virus Diseases [C02]
RNA Virus Infections [C02.782]
Retroviridae Infections [C02.782.815]
Lentivirus Infections [C02.782.815.616]
HIV Infections [C02.782.815.616.400]
HIV Seropositivity [C02.782.815.616.400.500]
Sexually Transmitted Diseases [C02.800]
Sexually Transmitted Diseases, Viral [C02.800.801]
HIV Infections [C02.800.801.400]
HIV Seropositivity [C02.800.801.400.500]
Immune System Diseases [C20]
Immunologic Deficiency Syndromes [C20.673]
HIV Infections [C20.673.480]
HIV Seropositivity [C20.673.480.500]

Below are MeSH descriptors whose meaning is related to "HIV Seropositivity".

Below are MeSH descriptors whose meaning is more specific than "HIV Seropositivity".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "HIV Seropositivity" by people in this website by year, and whether "HIV Seropositivity" was a major or minor topic of these publications.

Bar chart showing 54 publications over 20 distinct years, with a maximum of 8 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	3	4
1996	1	4	5
1997	2	1	3
2001	2	0	2
2003	2	1	3
2005	1	0	1
2006	1	1	2
2008	1	0	1
2009	1	1	2
2011	6	2	8
2012	3	0	3
2013	1	0	1
2014	2	1	3
2015	6	1	7
2016	0	2	2
2017	2	1	3
2019	1	0	1
2020	0	1	1
2022	1	0	1
2023	1	0	1

Below are the most recent publications written about "HIV Seropositivity" by people in Profiles.

Abeynaike SA, Huynh TR, Mehmood A, Kim T, Frank K, Gao K, Zalfa C, Gandarilla A, Shultz L, Paust S. Human Hematopoietic Stem Cell Engrafted IL-15 Transgenic NSG Mice Support Robust NK Cell Responses and Sustained HIV-1 Infection. Viruses. 2023 01 27; 15(2).

View in: PubMed
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 05 07; 399(10337):1779-1789.

View in: PubMed
Ruggiero A, Pascucci GR, Cotugno N, Dom?nguez-Rodr?guez S, Rinaldi S, Tagarro A, Rojo P, Foster C, Bamford A, De Rossi A, Nastouli E, Klein N, Morrocchi E, Fatou B, Smolen KK, Ozonoff A, Di Pastena M, Luzuriaga K, Steen H, Giaquinto C, Goulder P, Rossi P, Levy O, Pahwa S, Palma P. Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy. Front Immunol. 2022; 13:860418.

View in: PubMed
Ohainle M, Kim K, Komurlu Keceli S, Felton A, Campbell E, Luban J, Emerman M. TRIM34 restricts HIV-1 and SIV capsids in a TRIM5a-dependent manner. PLoS Pathog. 2020 04; 16(4):e1008507.

View in: PubMed
Luban J. The hidden cost of genetic resistance to HIV-1. Nat Med. 2019 06; 25(6):878-879.

View in: PubMed
Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, Pai SI, Sidransky D, Westra WH, William WN, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck. 2017 12; 39(12):2433-2443.

View in: PubMed
Do HP, Nguyen LH, Thi Nguyen NP, Ngo C, Thi Nguyen HL, Le GT, Nguyen LK, Nguyen CT, Tran BX, Le HT, Vu TMT, Phan HTT, Tran TD, Latkin CA, Dunne MP. Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam. BMJ Open. 2017 Jul 17; 7(7):e015889.

View in: PubMed
Merchant RC, Romanoff J, Clark MA, Liu T, Rosenberger JG, Bauermeister J, Mayer KH. Variations in Recruitment Yield and Characteristics of Participants Recruited Across Diverse Internet Platforms in an HIV Testing Study of Young Adult Men-Who-Have-Sex-With-Men (YMSM). Am J Mens Health. 2017 Sep; 11(5):1342-1357.

View in: PubMed
Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):271-279.

View in: PubMed
DeGregorio G, Manga S, Kiyang E, Manjuh F, Bradford L, Cholli P, Wamai R, Ogembo R, Sando Z, Liu Y, Sheldon LK, Nulah K, Welty T, Welty E, Ogembo JG. Implementing a Fee-for-Service Cervical Cancer Screening and Treatment Program in Cameroon: Challenges and Opportunities. Oncologist. 2017 07; 22(7):850-859.

View in: PubMed

People

Explore

Similar Concepts

Top Journals